HIV Vaccine Research & Development. Understanding the landscape – A Funders’ Briefing. Mitchell Warren Executive Director, AVAC 29 March 2012 Funders Concerned About AIDS. About AVAC. Founded in 1995
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Understanding the landscape – A Funders’ Briefing
Executive Director, AVAC
29 March 2012
Funders Concerned About AIDS
Source: AVAC Report 2007: Resetting the Clock
Albert Szent-Györgyi, 1937 Nobel Laureate in Medicine
GOAL: A sustained decline in HIV infections (now at 2.7 million/year)
Years to Impact
Zero to 5
5 to 10
In May 2011, the Pox-Protein Public Private Partnership or “P5” (formed by Sanofi Pasteur, Novartis, US NIH, Gates Foundation, the US MHRP and the HVTN) debuts, designed to move from the RV144 Thai prime-boost vaccine trial results to a potentially licensable product for Thailand and elsewhere.
In 2009, the RV144 Thai vaccine was the first ever to demonstrate a modest effect of 31.2% in preventing HIV infection. In September 2011, immune responses predictive of risk in RV144 trial identified.
In August 2011, the HVTN 505 Phase II trial of a DNA-Ad5 combination expands its scope to include an investigation of whether the experimental vaccine regimen prevents HIV infection.
More than two dozen phase I & II trials are ongoing in 20+ countries worldwide. Promising antibody and animal studies are continuing.
Follow-on studies from RV144 in South Africa and Thailand in devlelopmemt.
Series of ongoing discoveries of new neutralizing antibodies, that provide potential new targets for AIDS vaccine development
JanuaryFebruary March April May June JulyAugust September October November December
HVTN 205US, Peru
Phase II trial to assess safety of DNA and MVA vaccines and immune responses of participants to see if these vaccines are helpful in fighting HIV infection.
HVTN 505 US
Phase IIb trial to assess ifDNA prime/rAd5 boost vaccine regimensignificantly reduce viral load in individuals who become infected with HIV.
Phase I/II trial to assess the safety and immune response in the mucosa of the vector vaccines NYVAC-B and the rAd5.
Phase I/II trial to assess the safety and immune response of DNA priming and MVA boosting and to develop further HIV vaccine trial capacity building in Tanzania.
No effective HIV vaccine is available today; however, more than two dozen phase I & II trials are ongoing in 20+ countries around the world, including follow-on studies from recent large-scale trials.
Phase I/II trial to assess the safety and immune response of an adenovirus-based HIV-1 vaccine regimen.
Brazil, Peru, Switzerland, US
Phase I/II trial to assesses the safety and immune response of two Ad5 adenoviral vector vaccines.
Annual investments in HIV vaccine R&D 2000 – 2010 (US$ millions)
* Commercial sector estimates not available for years 2000 to 2004. For years available commercial funding figures are estimates based upon a review of HIV vaccine programs at each company.
** Other includes all national public sector funding apart from funding from the US and Europe.
US$ 859 million was spent on HIV Vaccine R&D in 2010: what was it spent on?
US$ 8,590,000 spent on advocacy & policy development in 2010 (1% of total)
US$ 51,540,000 spent on cohort & site development in 2010 (6% of total)
US$ 231,930,000 spent on basic research in 2010 (27% of total)
US$ 214,750,000 spent on clinical trials in 2010 (25% of total)
US$ 352,190,000 spent on pre-clinical research in 2010 (41% of total)
Advocacy & policy development
Cohort & site development